Sino Biopharmaceutical (HK:1177) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sino Biopharmaceutical has received approval to submit a marketing application for its innovative drug combination, Benmelstobart Injection and Anlotinib Hydrochloride Capsules, aimed at treating the ultra-rare alveolar soft part sarcoma (ASPS). With a high tendency for metastasis and limited treatment options, this new combination therapy offers hope for improved outcomes in ASPS patients. This development marks a significant step for Sino Biopharmaceutical in expanding its portfolio of effective cancer treatments.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
